Phyllis Arthur's Testimony to Senate HELP Committee on Lessons Learned from Covid-19
July 27, 2021
COVID-19 will not be our last public health emergency. We face numerous bio-threats from natural and bioterror threats. Strong support for medical countermeasures R&D is critical to protecting our national security.
Today I will share BIO’s thoughts on how to strengthen our national preparedness through coordinated leadership, expanded partnership with industry and better public health infrastructure.
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.
COVID-19 will not be our last public health emergency. We face numerous bio-threats from natural and bioterror threats. Strong support for medical countermeasures R&D is critical to protecting our national security.
Today I will share BIO’s thoughts on how to strengthen our national preparedness through coordinated leadership, expanded partnership with industry and better public health infrastructure.